CytomX Therapeutics (CTMX) Earnings Call Presentation

Financials & Organization - The company had approximately $101 million in cash balance as of year-end 2024, which is expected to fund operations into Q2 2026, excluding potential milestones or new business development[6] - The company's organization consists of approximately 70 employees with integrated R&D capabilities[6] Clinical Pipeline (CX-2051) - CX-2051 (EpCAM PROBODY® Topo-1 ADC) is being developed for advanced CRC, with initial Phase 1 data expected in the first half of 2025 and determination of Phase 1b doses[7, 8] - Over 90% of CRC cases are estimated to have high EpCAM expression, making it a relevant target for CX-2051[32, 33] - In preclinical models, CX-2051 demonstrated >100x masking efficiency by ELISA and equivalent preclinical activity to deruxtecan (DXd) in irinotecan-resistant CRC models[22, 25] Clinical Pipeline (CX-801) - CX-801 (PROBODY® IFN-α2b) is being developed for advanced melanoma, with initial Phase 1 translational & biomarker data expected in the second half of 2025, and initiation of Keytruda® combination[7, 8] - Preclinical data suggests CX-801 has synergistic activity with PD-1 inhibitors and enhanced safety compared to unmasked IFNα2b[55] - CX-801 demonstrated 1000X masking efficiency based on preclinical models[54] Strategic Focus - The company is focused on addressing major unmet needs in oncology with its PROBODY® pipeline[4, 71] - The company plans to determine Phase 1b doses for potential CRC expansions and evaluate strategies for CRC combinations and additional tumor types for CX-2051[47, 72]